CAP-BOP                                              lymphoma(85)
 _________________________________________________________________
  cytoxan......... 650 mg/sqm IV day 1.
  adriamycin...... 50 mg/sqm IV day 1.
  procarbazine.... 100 mg/sqm/day orally from day 1 to day 7.
  bleomycin....... 10 U/sqm SC day 15.
  vincristine..... 1.4 mg/sqm IV day 15.
  prednisone...... 100 mg/day orally from day 15 to 21.
  FREQUENCY....... Repeat cycle at 21 to 28 day intervals to 
                   documented complete remission and then give two 
                   more cycles.


  reference...
    Armitage JO.  Weisenburger DD.  Hutchins M.  Moravec DF.  
    Dowling M. Sorensen S.  Mailliard J.  Okerbloom J.  Johnson 
    PS.  Howe D.  et al. Chemotherapy for diffuse large-cell 
    lymphoma--rapidly responding patients have more durable 
    remissions. Journal of Clinical Oncology.  4(2):160-4, 1986 
    Feb. 
  abstract...
    Fifty-one patients with diffuse large-cell lymphoma (DLCL) 
    were treated with a six-drug combination chemotherapy regimen 
    including cyclophosphamide, doxorubicin, procarbazine, 
    bleomycin, vincristine, and prednisone. The patients were 
    restaged after three cycles of therapy, and restaging was 
    repeated at 2-month intervals in patients who had persistent 
    disease. Responding patients received two cycles of therapy 
    after documentation of complete remission (CR). With all 
    patients considered evaluable, 73% of the patients achieved a 
    CR. Twenty-six of the 37 CRs (70%) achieved remission in the 
    first three treatment cycles. The durability of remission in 
    the rapidly responding patients was significantly better than 
    for patients who required five cycles to achieve CR (80% v 40% 
    at 2 years, P = .02) despite the latter patients having 
    received two more cycles of therapy. Rapidly responding 
    patients with DLCL do not require prolonged therapy and have a 
    better prognosis than patients achieving a CR more slowly.